During the last two years (with the support of the **DSLRF Grant Award 2007**), we have mainly focused our attention on both **1)**the involvement of oxidative stress in breast microenvironment and **2)**the function of adhesion molecules in the breast cells of the ductal-lobular unit.

**1)**Starting from our previous evidence that active lipid peroxidation may have a physiologic role in the normal mammary gland and that lower levels of isoprostanes in NAF of BC patients suggest altered arachidonate metabolism (Mannello et al, Int J Cancer 2007;120:1971--6), we have recently discovered that in NAF **Phospholipase A2-IIa**activity (key enzyme regulating arachidonate metabolism) may play a dual role in breast microenvironment during cancer development and progression. It shows a *beneficial*role releasing low Arachidonate levels in physiologic status, while its up-regulation has *detrimental*functions allowing the conversion of high arachidonate levels into leukotrienes and prostaglandins, promoting BC progression.

Noteworthy, the inhibition of this pathway through COX-inhibitors leads to induction of apoptosis and tumor growth reduction (Figure [1](#F1){ref-type="fig"}).

![](1753-6561-3-S5-S10-1){#F1}

**2)**Based on our hypothesis that peculiar junctional complexes may differently seal breast ductal cells leading them to different evolution (Mannello et al, Breast Cancer Res Treat 2007;102:125), we have recently discovered that higher levels of **soluble form of P-cadherin**were found in NAF from cancer patients. We found a positive correlation of sP-cad with disease stages and tumor grade, and an inverse relationship with estrogen/progesterone receptor status. High levels of sP-cad in cancer NAF suggest its release via proteolytic processing, favouring cancer cell detachment from breast duct.

**3)**Moreover, we have found that breast epithelial cells floating in NAF of cancer patients contain higher concentrations of **Erythropoietin**which may be shed in NAF, triggering intracellular signal cascade with subsequent breast cancer initiation. These results may explain the controversies of preclinical/clinical studies about the use of **Epo**, (i.e., beneficial role improving patient\' survival and negative impact promoting tumor growth progression)

**4)**We overviewed how **Diet nutrients**may regulate in breast microenvironment both NAF protein expression and cancer etiology. We also reviewed how the **Intraductal approaches**assessing metabolic changes in breast microenvironment may help to identify early breast cancer biomarkers in NAF. Finally, we critically overviewed and discussed how the **Protein analyses**of NAF (mirroring the breast microenvironment) may differentiate healthy women from breast cancer patients.
